Table 1.
Tissue sample characteristics.
| No Prior Neoadjuvant Chemotherapy Treatment (Non-NCT) (%) (N = 31) |
Neoadjuvant Chemotherapy Treatment (NCT) (%) (N = 35) |
|
|---|---|---|
| Tumor grade | ||
| Well Differentiated | 6 (19.4%) | 9 (25.7%) |
| Moderately Differentiated | 15 (48.4%) | 16 (45.7%) |
| Poorly Differentiated | 10 (32.3%) | 10 (28.6%) |
| Primary tumor designation | ||
| T1 | 5 (16.1%) | 11 (31.4%) |
| T2 | 11 (35.5%) | 20 (57.1%) |
| T3 | 14 (45.2%) | 3 (8.6%) |
| T4 | 1 (3.2%) | 1 (2.9%) |
| Lymph node designation | ||
| N0 | 7 (22.6%) | 15 (42.9%) |
| N1 | 18 (58.1%) | 16 (45.7%) |
| N2 | 6 (19.4%) | 4 (11.4%) |
| Metastatic disease designation | ||
| MX | 4 (12.9%) | 7 (20%) |
| M0 | 26 (83.9%) | 28 (80%) |
| M1 | 1 (3.2%) | 0 (0%) |
| AJCC Stage | ||
| IA | 3 (9.7%) | 6 (17.1%) |
| IB | 2 (6.5%) | 10 (28.6%) |
| IIA | 11 (35.5%) | 14 (40%) |
| IIB | 10 (32.3%) | 4 (11.4%) |
| IIIA | 3 (9.7%) | 0 (0%) |
| IIIB | 1 (3.2%) | 1 (2.9%) |
| IV | 1 (3.2%) | 0 (0%) |
| Fibrosis classification | ||
| All tumor | 1 (3.2%) | 1 (2.9%) |
| More tumor than fibrosis | 20 (64.5%) | 9 (25.7%) |
| More fibrosis than tumor | 10 (32.3%) | 25 (71.4%) |
| All fibrosis | 0 (0%) | 0 (0%) |
| Neoadjuvant therapy treatment | ||
| FOLFIRINOX-based | NA | 14 (40%) |
| FOLFIRINOX + radiation | NA | 17 (48.6%) |
| Gemcitabine-based | NA | 4 (11.4%) |
| Grade of pathological response | ||
| No response | NA | 1 (2.86%) |
| Minimal response | NA | 14 (40%) |
| Moderate response | NA | 17 (48.57%) |
| Marked response | NA | 3 (8.57%) |